交感神经节在支配心脏中的作用研究进展

交感神经可支配心脏,并在心脏传导、调节心率、心肌收缩和舒张等方面具有重要作用。目前对支配心脏的交感神经的研究多数集中在心肌组织中分布的交感神经,实际上支配心脏的远端交感神经节(颈部神经节和星状神经节)也发挥着重要作用。文中简要介绍了交感神经节对心脏的支配情况,总结了交感神经节阻滞在心脏疾病治疗中的作用,讨论了交感神经节支配心脏的作用机制方面的研究现况,提出了可以应用细胞电生理、免疫组化分析、分子生物学等技术,对支配心脏的远端交感神经节在心脏疾病、药物及物理因子作用下的机制进行研究。这将对深层次揭示心脏疾病的发病机制及相关治疗药物和物理方法的研制提供一定的理论及实验参考。     

神经干细胞研究进展

神经干细胞(neural stem cells, NSCs)是中枢神经系统中保持分裂和分化潜能的细胞,对它的研究和应用已成为近年来脑科学研究的一个重要领域.神经干细胞体外培养技术的建立提供了对其进行研究的有力手段.目前的研究主要集中于神经干细胞在脑中的起源、分布及在中枢神经系统疾病治疗中的应用等方面.     

微流控芯片在心肌细胞功能研究中的应用

心肌细胞是心脏结构和功能的基本单位,约占心脏细胞总数的三分之一,是心脏发育、生理病理研究的重点对象,然而传统的在体和体外研究技术存在诸多困难,无法实现细胞微环境的有效控制和生理功能的实时动态监测,制约着心肌细胞功能研究的快速发展。近年来迅速发展的微加工技术,尤其是微流控芯片技术为心肌细胞功能研究提供了便利。微流控芯片技术具有微米尺度的细胞及其微环境的时空控制功能,有效提高了体外细胞研究的组织相关性,是心肌细胞生理功能和力学特性研究的重要工具,如实时监测单个心肌细胞的代谢活性、表征细胞的电生理特性和力学特性、研究细胞微环境和力学微环境对心肌细胞形态和功能的影响。本文从前述几个方面对微流控芯片在心肌细胞生理功能研究中的应用进行综述和对其应用前景进行了展望。     

心脏类器官

类器官是体外构建的一类由多种类型细胞组成的,与体内器官或组织高度相似的三维培养物,它能够模拟细胞所属器官的某些结构和生理功能。心血管疾病患病率及死亡率一直处于上升阶段,相关基础研究主要基于细胞和动物模型。心脏类器官是对传统心血管疾病模型的有效补充,在体外更真实和准确地反映人体心脏的生物学特性和功能,使其在疾病机制研究、药物开发、精准医疗和再生医学等领域具有广泛应用前景和独特优势。该文主要介绍了心脏类器官作为新一代疾病模型在心肌梗死、心力衰竭、遗传性心脏病和心律失常等方面的应用,并探讨了类器官技术未来的发展方向和面临的挑战。     

子宫内膜异位细胞改良体外培养技术的研究进展

体外细胞培养是子宫内膜异位性疾病研究的重要工具.本文回顾了细胞体外培养技术在分离、纯化环节的改良以及子宫内膜异位性疾病永生化细胞系改造中的研究进展,并总结了近几年来激素及细胞因子诱导培养、细胞共培养及三维培养技术在该疾病体外机制研究中的应用,并对其发展前景进行了展望.     

超声技术在抑郁症诊疗中的作用研究及应用进展

超声波作为一种机械振动波,兼具波动效应、力学效应和热效应.这3种效应在临床中均有较大应用价值,可用于疾病的成像诊断、辅助给药、调控以及热消融治疗等.超声技术所具有的非侵入性、穿透力强、空间分辨率高等特性,使其在神经系统疾病的诊断和治疗中具有广泛的应用前景.而抑郁症作为一种常见的精神疾病,其诊断和治疗都面临很大的困难.因此,大量学者将超声技术应用于抑郁症诊疗.本文主要从超声成像、超声定点给药、超声调控、超声诱导抑郁几个方面总结近十年来超声技术在抑郁症中的应用,以期为研究抑郁症发病机制及诊疗提供一定的参考和帮助.     

与心脏发育相关的miRNA研究

microRNA（miRNA）是生物体内源长度约为20～23个核苷酸的非编码小RNA,在生物体发育、细胞增殖与分化等过程中扮演了重要角色。心脏是人体的重要器官之一,miRNA与心脏发育密切相关,很多分子生物学研究技术已经应用到对心脏发育的研究中,研究表明一些特异miRNA有可能为心脏疾病的诊断和治疗提供新的靶点和研发新的药物。     

心脏发育和疾病的表观遗传调控机制

表观遗传调控机制是后基因组时代的重点研究领域,当前许多证据表明表观遗传学调控心脏发育进程,参与多种心脏疾病的调控。本文综述了DNA甲基化、组蛋白修饰、染色质重塑复合物和microRNAs在心脏发育中的作用,以及在动脉粥样硬化、心力衰竭、心肌缺血、心肌纤维化等心脏疾病中表观遗传调控的研究进展,同时概述了生物活性食品化合物在心脏保护中的作用,为心脏发育的分子机制研究和心脏疾病的预防与治疗方向提供新的视角。     

人类多能干细胞源心肌细胞的研究进展与应用前景

人类多能干细胞(human pluripotent stem cells,hPSC)具有无限增殖的能力并可体外分化成心肌细胞,可作为新型的细胞源用于心脏疾病的细胞替代疗法、药物检测及心脏发育生物学的基础研究。hPSC包括人胚胎干细胞(human embryonic stem cells,hESC)和诱导型人多能干细胞(human induced pluripotent stem cells,hiPSC),后者的出现不仅使干细胞个性化治疗成为可能,同时规避了人胚胎干细胞应用的医学伦理问题,具有较大的发展空间。尽管hPSC源心肌细胞的应用研究已取得极大进展,但将这种心肌细胞应用于临床仍有许多技术问题需要解决。该文将综述hPSC源心肌细胞的技术进展,探讨hPSC源心肌细胞的应用前景,并对存在的问题和挑战也进行了讨论。     

体外功能性肺组织模型构建、调控及在肺纤维化和COVID-19中的应用

肺纤维化是很多肺部疾病发生发展过程中出现的病理现象。近年出现的2019冠状病毒病(coronavirus disease 2019, COVID-19)引发的呼吸系统综合征也会出现弥漫性肺泡损伤,并诱发肺纤维化。因此,开展肺纤维化和COVID-19体外模型构建与调控研究在肺部疾病治疗和药物筛选方面意义重大。目前,现有研究已建立了多种体外肺组织二维、三维细胞培养模型,本文将全面概述这些模型的构建方法,并结合这些模型在肺纤维化及COVID-19中的应用研究,对体外肺组织模型在药物传递、高通量药物筛选及发病机制研究等生物医学领域中的应用前景进行综述,为其进一步研究提供参考。     

Diagnostic ultrasound-mediated microbubble cavitation dose-dependently improves diabetic cardiomyopathy through angiogenesis

Ultrasound-mediated microbubble cavitation (UMMC) induces therapeutic angiogenesis to treat ischemic diseases. This study aimed to investigate whether diagnostic UMMC alleviates diabetic cardiomyopathy (DCM) and, if so, through which mechanisms. DCM model was established by injecting streptozocin into rats to induce hyperglycemia, followed by a high-fat diet. The combined therapy of cation microbubble with low-intensity diagnostic ultrasound (frequency = 4 MHz), with a pulse frequency of 20 Hz and pulse length (PL) of 8, 18, 26, or 36 cycles, was given to rats twice a week for 8 consecutive weeks. Diagnostic UMMC therapy with PL at 8, 18, and 26 cycles, but not 36 cycles, dramatically prevented myocardial fibrosis, improved heart functions, and increased angiogenesis, accompanied by increased levels of PI3K, Akt, and eNOS proteins in the DCM model of rats. In cultured endothelial cells, low-intensity UMMC treatment (PL = 3 cycles, sound pressure level = 50%, mechanical index = 0.82) increased cell viability and activated PI3K-Akt-eNOS signaling. The combination of diagnostic ultrasound with microbubble destruction dose-dependently promoted angiogenesis, thus improving heart function through PI3K-Akt-eNOS signaling in diabetes. Accordingly, diagnostic UMMC therapy should be considered to protect the heart in patients with diabetes.     

超声空化效应和超声微泡在生物医学中的应用

近年来,随着超声技术在医疗领域的广泛应用及超声造影剂研制的进展,空化效应和超声造影剂协同运用作为一种高效、安全、操作简单,且具有一定靶向性的无创治疗手段,在基因治疗、药物输送、溶栓和治栓,以及炎症与肿瘤的靶向诊断与治疗方面显示了巨大的运用潜力。简要综述了超声空化效应和超声微泡的治疗机制及应用。     

三维超声心脏图像的模糊聚类分割

采用三维超声心动图对小儿先天性心脏病进行诊断与治疗能达到比传统二维超声心动图更直观的效果。然而由于超声图像质量较差,三维超声心动图的可视化效果往往无法达到医生的要求。本文对三维超声心脏图像进行分割,以改进超声图像的可视化效果,并为参数提取等提供基础。首先采用快速的模糊c均值聚类得到初始分割结果;然后利用图像多分辨率技术进行修正;接着结合图像的对比度进行进一步的分割;最后,把处理后的图像用绘制的方法显示出来。本文的结果对超声图像的可视化效果有一定的改善.     

Emerging technologies in therapeutic ultrasound: Thermal ablation to gene delivery

Ultrasound is used today in medicine as a modality for diagnostic imaging. Recently, there have been numerous reports on the application of thermal and nonthermal ultrasound energy for treating various diseases. In addition to thermal ablation of tumors, non-thermal ultrasound combined with drugs and genes have led to much excitement especially for cancer treatment, vascular diseases, and regenerative medicine. Ultrasound energy can enhance the effects of thrombolytic agents such as urokinase for treatment of stroke and acute myocardial infarction. New ultrasound technologies have resulted in advanced devices such as a) ultrasound catheters, b) Non-invasive methods as high intensity focused ultrasound (HIFU) in conjunction with MRI and CT is already being applied in the clinical field, c) Chemical activation of drugs by ultrasound energy for treatment of tumors is another new field recently termed “Sonodynamic Thew”, and d) Combination of genes and microbubble have induced great hopes for ideal gene therapy (sonoporation). Various examples of ultrasound combined modalities are under investigation which could lead to revolutionary therapy.     

Molecular mechanism and therapy application of necrosis during myocardial injury

Necrosis is an ancient topic which gains new attraction in the research area these years. There is no doubt that some necrosis can be regulated by genetic manipulation other than an accidental cell death resulting from physical or chemical stimuli. Recent advances in the molecular mechanism underlying the programmed necrosis show a fine regulation network which indicates new therapy targets in human diseases. Heart diseases seriously endanger our health and have high fatality rates in the patients. Cell death of cardiac myocytes is believed to be critical in the pathogenesis of heart diseases. Although necrosis is likely to play a more important role in cardiac cell death than apoptosis, apoptosis has been paid much attention in the past 30 years because it used to be considered as the only form of programmed cell death. However, recent findings of programmed necrosis and the related signalling pathways have broadened our horizon in the field of programmed cell death and promote new pharmacological application in the treatment of heart diseases. In this review, we summarize the advanced progress in these signalling pathways and discuss the pathos‐physiological relevance and therapeutic implication of targeting necrosis in heart diseases treatment.     

肿瘤基因治疗的研究进展

基因治疗作为一种新的治疗手段,给许多绝症患者带来希望。基因治疗的范围已从最初的单基因疾病扩展到恶性肿瘤、心脑血管及自身免疫等诸多领域,其中以恶性肿瘤为主要对象。本文综述了肿瘤基因治疗中的基因转移方法、基因治疗策略、导向基因治疗及其在应用上的问题与展望。     

Fetal monitoring during maternal cardiac surgery with cardiopulmonary bypass.

Fetal cardiac activity was monitored with an external ultrasound transducer in two patients with clinical class III heart disease due to severe mitral stenosis complicated by pulmonary hypertension, undergoing open heart surgery with cardiopulmonary bypass in the 2nd trimester of pregnancy. Fetal distress was detected in one patient, who had mitral valvuloplasty, and was corrected by increasing the rate of blood flow, and the other patient had a mitral valve replacement but no fetal distress was noted. The postoperative course of both mothers and fetuses was uneventful.     

Emerging technologies in therapeutic ultrasound: Thermal ablation to gene delivery

Ultrasound is used today in medicine as a modality for diagnostic imaging. Recently, there have been numerous reports on the application of thermal and nonthermal ultrasound energy for treating various diseases. In addition to thermal ablation of tumors, non-thermal ultrasound combined with drugs and genes have led to much excitement especially for cancer treatment, vascular diseases, and regenerative medicine. Ultrasound energy can enhance the effects of thrombolytic agents such as urokinase for treatment of stroke and acute myocardial infarction. New ultrasound technologies have resulted in advanced devices such as a) ultrasound catheters, b) Non-invasive methods as high intensity focused ultrasound (HIFU) in conjunction with MRI and CT is already being applied in the clinical field, c) Chemical activation of drugs by ultrasound energy for treatment of tumors is another new field recently termed "Sonodynamic Therapy", and d) Combination of genes and microbubble have induced great hopes for ideal gene therapy (sonoporation). Various examples of ultrasound combined modalities are under investigation which could lead to revolutionary therapy.     

Measurement of hemodynamics in human carotid artery using ultrasound and computational fluid dynamics.

The objective of the study was to investigate the feasibility of using computational fluid dynamic modeling (CFD) with noninvasive ultrasound measurements to determine time-variant three-dimensional (3D) carotid arterial hemodynamics in humans in vivo. The effects of hyperoxia and hypoxic hypercapnia on carotid artery local hemodynamics were examined by use of this approach. Six normotensive volunteers followed a double-blind randomized crossover design. Blood pressure, heart rate, and carotid blood flow were measured while subjects breathed normal air, a mixture of 5% CO(2) and 15% O(2) (hypoxic hypercapnia), and 100% O(2) (hyperoxia). Carotid artery geometry was reconstructed on the basis of B-mode ultrasound images by using purpose-built image processing software. Time-variant 3D carotid hemodynamics were estimated by using finite volume-based CFD. Systemic blood pressure was not significantly affected by hyperoxia or hypoxic hypercapnia, but heart rate decreased significantly with hyperoxia. There was an increase in diastolic flow velocity in the external carotid artery after hypoxic hypercapnia, but otherwise carotid blood flow velocities did not change significantly. Compared with normal air, hyperoxic conditions were associated with a decrease in the width of the region of flow separation in the external carotid artery. During hyperoxia, there was also an increase in the minimum and a decrease in maximum shear stress in the bifurcation and hence a reduction in cyclic variation in shear stress. Hypoxic hypercapnia was associated with a reduced duration of flow separation in the external carotid artery and an increase in the minimum shear stress without affecting the cyclic variation in shear stress. This study demonstrates the feasibility of using noninvasive ultrasound techniques in conjunction with CFD to describe time-variant 3D hemodynamics in the human carotid arterial bifurcation in vivo.     

Management of Malassezia-related diseases in the dog

Most cases of Malassezia dermatitis/otitis in the dog are associated with concurrent dermatoses or systemic diseases and recurrences are not uncommon. Recognition and control of the predisposing factors are therefore key factors for successful therapy and prevention of recurrent infections. Currently, Malassezia dermatitis/otitis is managed by the use of antifungal drugs. Systemic therapy is often necessary, in particular when clinical signs are severe and widespread. Ketoconazole and Itraconazole are the most commonly used drugs. Topical therapy is an alternative in case of localized lesions and external ear localizations. Different commercial formulations, available in clinical practice in form of creams, gels, lotions, sprays and ear drops are often used as adiuvants to systemic therapy. Topicals more frequently used are represented by imidazolic antifungals, chlorhexydine and lime sulphur. The presentation deals with more recent advances about the protocols for treatment of Malassezia-related diseases in the dog. New perspectives, as the use of natural compounds, immunotherapy and inhibitors of yeast adherence factors, are also discussed.